14th European Congress of Clinical Microbiology and Infectious ...

Poster Sessions Monday, May 3, 2004
P1057 Bac protein based recombinant peptides as
possible means for vaccine development
against GBS infection
L. Meringova, I. Ustinovitch, K. Grabovskaya,
G. Leontieva, A. Suvorov (St.Petersburg, RUS)
P1060 Bacterial adherence ability and adherence
factors of quinolone sensitive and resistant
E. coli strains isolated from cirrhotic patients
I. Gascón, P. Más, R. Francés, S. Pascual,
V. Merino, J. Such, J. Plazas
(Alicante, Valencia, E)
P1061 Effect of quinolones on the induction of the
loss of pathogenicity islands in uropathogenic
Escherichia coli
S.M. Soto, J.P. Horcajada, J. Mensa,
M.T. Jiménez de Anta, J. Vila (Barcelona, E)
P1062 Use of deletion mutations to explore
structure-function relationships in
Clostridium tetani neurotoxin
I. Belyi (Moscow, RUS)
P1063 The contribution of a subspecies-specific type
IV secretion system to pathogenicity in
Campylobacter fetus venerealis
G. Gorkiewicz, C. Schober, S. Scheicher,
S. Kienesberger, R. Zechner, E. Zechner (Graz, A)
P1064 The role of the SabA adhesin and other
Helicobacter pylori virulence factors in
activation of human neutrophils
M. Unemo, D. Ilver, D. Danielsson, M. Hurtig,
T. Borén, S. Teneberg (Örebro, S)
P1065 Characterisation of the penetration ability and
cytotoxicity of Serratia marcescens
L.-H. Su, C.-H. Chiu, C. Chu, T.-L. Wu, J.T. Ou,
T.V. Riley, B.J. Chang (Taoyuan, TW; Perth, AUS)
P1066 Modulation of Listeria monocytogenes
interaction with cellular substrate by
ß-lactam antibiotics and human serum
transferrin
G. Mihaescu, B. Manolescu, L. Petrache
(Bucharest, RO)
P1067 Treponema pallidum pallidum (strain Nichols),
but not Treponema phagedenis (biotype
Reiter), has an apical structure that may be a
pathogenic factor
A. Magalhães-Sant'Ana, C. Nogueira, G. Marrão,
G. Rocha (Coimbra, P)
P1068 Route of natural exposure in animal model of
brucellosis
Z. Yumuk, S. Caliskan, D. Dundar, V. Dundar
(Kocaeli, TR)
page 100 Final Programme
12:00–13:00
Insights into hepatitis
P1069 Efficacy of lamivudine in treatment of precore
mutant chronic hepatitis B
M.R. Hasanjani Roushan, M.A. Shafai,
S.A. Asgharzadeh Ahmadi (Babol, IR)
P1070 Molecular epidemiology of hepatitis B in
Denmark
N. Fisker, C. Pedersen, M. Lange, N.T.T. Nguyen,
K.T.T. Nguyen, J. Georgsen, P.B. Christensen
(Odense, DK)
P1071 Much gained by integrating contact tracing
and vaccination in the hepatitis B antenatal
screening programme in Amsterdam,
1992–1999
J.E. van Steenbergen, D. Baayen,
P.G.H. Peerbooms, R.A. Coutinho,
J.A.R. van den Hoek
(Utrecht, Amsterdam, Netherlands, NL)
P1072 Different B2-microglobulin (b2m) curves in
chronic hepatitis B (CHB) patients, under
long-term lamivudine (LAM) monotherapy or
interferon plus lamivudine (IFN/LAM)
combination treatment. Relationship with
virological breakthrough (VB)
I.S. Elefsiniotis, K.D. Pantazis, I. Glynou,
N.V. Fotos, C. Mavrogiannis, H. Kada
(Athens, GR)
P1073 Psychiatric adverse effects of interferon alpha
2a treatment in chronic hepatitis patients
N. Kaya, E. Turk Aribas, A.C. Inkaya, M. Bitirgen
(Konya, TR)
P1074 The prevalence of hepatitis B virus precore
mutant in patients with chronic hepatitis B
virus infection
F. Yarkin, Z. Altun, O. Bayramoglu, N. Saltoglu,
F. Koksal (Adana, TR)
P1075 Antigenic property of different sequence
variants of the hepatitis B surface antigen
wild types and vaccine escape mutants
T. Ulanova, J. Yokosawa, A. Burkov, V. Puzyrev,
A. Obriadina
(Nizhniy Novgorod, RUS; Atlanta, USA)
P1076 Performance of hepatitis B surface antigen
(HBsAg) assays for the detection of
recombinant and native HBsAg mutants and
screening for HBsAg mutants in isolated anti-
HBc positive sera
B. Weber, N. Van Der Taelem-Brulé
(Junglinster, LUX)